Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Dividend investing for retirement -- Ignore unavailable to you. Want to Upgrade?

To: Ditchdigger who wrote (26769)	3/7/2017 10:03:15 AM
From: E_K_S	Respond to of 34328

All eyes on healthcare with GOP bill out. . . Trump tweets about a "new system" to lower drug prices; IBB down 1% premarket The iShares Nasdaq Biotechnology Index Fund (IBB) is down 1% premarket on average volume as is the SPDR S&P Biotech ETF (XBI). Top biotechs are also down ~1% premarket: (NASDAQ:GILD)(NASDAQ:BIIB)(NASDAQ:AMGN), Shire (NASDAQ:SHPG) down 2%, Perrigo (NASDAQ:PRGO) down 2%, Mylan (NASDAQ:MYL) down 1%, Valeant Pharmaceuticals (NYSE:VRX) down 1%. ------------------------------------------------------- Still too early to tell but Drug stock selling off hinting there may be some price disruption. No idea if that may/could impact Pharma dividends. Medical REITs off a bit but very small. EKS